Skip to main content

Peer Review reports

From: Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Original Submission
29 Jul 2014 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Resubmission - Version 4
Submitted Manuscript version 4
Author responded Author comments
Resubmission - Version 5
Submitted Manuscript version 5
Resubmission - Version 6
Submitted Manuscript version 6
Author responded Author comments
Resubmission - Version 7
Submitted Manuscript version 7
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 8
Submitted Manuscript version 8
Author responded Author comments
Resubmission - Version 9
Submitted Manuscript version 9
Resubmission - Version 10
Submitted Manuscript version 10
Author responded Author comments
Resubmission - Version 11
Submitted Manuscript version 11
Publishing
9 Oct 2015 Editorially accepted
21 Oct 2015 Article published 10.1186/s12885-015-1751-6

You can find further information about peer review here.

Back to article page